Media headlines about BioSpecifics Technologies (NASDAQ:BSTC) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioSpecifics Technologies earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.058400172777 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of NASDAQ:BSTC traded up $0.06 during trading on Thursday, hitting $44.15. 21,422 shares of the company traded hands, compared to its average volume of 27,886. The firm has a market capitalization of $316.33, a PE ratio of 25.97 and a beta of 1.43. BioSpecifics Technologies has a one year low of $38.05 and a one year high of $58.79.
Several analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of BioSpecifics Technologies in a report on Tuesday, December 26th. Zacks Investment Research lowered BioSpecifics Technologies from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 27th. Finally, BidaskClub raised BioSpecifics Technologies from a “strong sell” rating to a “sell” rating in a report on Saturday, March 24th.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.